Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Current Liabilities (2023 - 2025)

Immunome's Total Current Liabilities history spans 3 years, with the latest figure at $45.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 17.16% year-over-year to $45.0 million; the TTM value through Dec 2025 reached $45.0 million, down 17.16%, while the annual FY2025 figure was $45.0 million, 17.16% down from the prior year.
  • Total Current Liabilities reached $45.0 million in Q4 2025 per IMNM's latest filing, up from $31.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $54.3 million in Q4 2024 to a low of $21.8 million in Q4 2023.
  • Average Total Current Liabilities over 3 years is $32.6 million, with a median of $30.8 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 148.78% in 2024, then tumbled 42.66% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $21.8 million in 2023, then skyrocketed by 148.78% to $54.3 million in 2024, then dropped by 17.16% to $45.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Total Current Liabilities are $45.0 million (Q4 2025), $31.4 million (Q3 2025), and $22.9 million (Q2 2025).